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19 All substances  are  poisons.  There is  none which  is  not a 
20 poison. The right  dose differentiates  a poison and a remedy 
21 (Paracelsus: 1493–1541) 
22 Toxicology  is the  study of  the  nature,  effects and 
23 detection  of  poisons and  the  treatment  of  poisoning. 
24 Poisons can be substances that are inherently toxic to 
25 tissues, adversely affect physiological function or thera- 
26 peutic substances taken in excess. Injury can result not 
27 only from the direct effects of the poison but indirectly 
28 from injuries sustained while the patient is intoxicated or 
29 in  various  phases of  withdrawal.  This  is  particularly 
30 relevant to those affected by sensorium altering substances 
31 such as opioids, cocaine, amphetamines, ketamine or with 
32 compounds emerging from clandestine  labs purporting to 
33 produce ‘legal highs’ or ‘herbal highs’. Anaesthetists use 
34 actual (e.g. muscle relaxants) or potential poisons daily but 
35 are either capable of managing their effects (e.g. venti- 
36 lation) or carefully titrate their administration to avoid 
37 toxicity and will be already familiar with the pharma- 
38 cology of many of these substances. The drugs may also 
39 interact with those used peri-operatively and therefore it 
40 is  apposite  to   understand  the   toxicology  of   these 
41 substances, when  practising in  anaesthesia or  intensive 
42 care. This review will focus on illicit substances. These 
43 have been a problem, of course, for many years but the 
44 range of drugs is increasing along with  accessibility   as 
45 many of these substances can be manufactured in illegal 
46 laboratories and even sold via the internet. We will first 
47 place the  problems  in  context,  provide some succinct 
48 information on some of the compounds, with anaesthetic 
49 implications where available, and conclude with recent 
50 developments in managing patients following ingestion. 
51 Since i  has not  been possible to study many of these t
u52 compo nds in clinical trials or even in humans as  they 
53 may have no therapeutic indication, the evidence base for 
anaesthetic implications is  rather  thin,  based on  case 
reports and ⁄ or anecdotal experience. Although numeri- 
cally important, opioid and benzodiazepine overdose will 
not be covered here as the pharmacological and toxico- 
logical aspects should  be  sufficiently familiar to  most 
anaesthetists. 
 
 
Epidemiology of poisoning 
 
Poisoning can affect  all age groups. Figures from  the 
Centre for Disease Control and Prevention estimated that 
in 2009, 41,592 poisoning deaths occurred in the United 
States, three quarters of which were deemed uninten- 
tional. This was second only to motor vehicle accidents  as 
a cause of unintentional injury and death for all ages. It 
was estimated that in the preceding year over 91 per cent 
of such deaths were caused by drugs, most commonly 
analgesics, which includes methadone, hydrocodone and 
oxycodone, followed by cocaine and heroin [1]. Across 
England and Wales, figures from the Office for National 
Statistics showed that of the 2747 drug poisoning deaths 
in 2010, 1784 were attributable to drug misuse and, again, 
most commonly associated with heroin and morphine. 
Opioids still dominate among the substances of abuse to 
be implicated as a cause of death, but cocaine, amphet- 
amines and the newer psychoactive substances together 
come close to one tenth of deaths [2]. 
Those that manage to make it into the statistics may 
represent the tip of the iceberg. Based on data from the 
British Crime Survey of 2009 ⁄ 2010, it is estimated  that in 
the  16–59 age group,  6.6% had  used cannabis, 2.4% 
powdered cocaine and 1.6% ecstasy in the year of the 
survey [3]. Drug intoxicated individuals may be accident 
prone,  from both  compromised judgement and motor 
skills. The latter is supported by data from Norway where 
 
  2012 The Authors 
Journal  compilation     2012 The Association of Anaesthetists  of Great Britain and Ireland 1 
 
Wong and Irwin Æ Poisoning with illicit substances 
 
Anaesthesia, 2012 1 
..................................................................................................................................................................................................................... 
 
1 close to three quarters of drivers with blood positive only 
2 for amphetamines and methamphetamines were perfor- 
3 mance-impaired in clinical testing [4]. 
4 
5 
Historical perspective of substances of abuse 6 
7 A more detailed review on this interesting area can be 
8 found in an editorial by King and Kicman [5] and a brief 
9 summary is provided here. Since 2005, the term ‘new 
10 psychoactive substances’ has been adopted by the Euro- 
11 pean Community to describe what was once referred to as 
12 ‘designer drugs’ or ‘legal highs’. Traditional drugs of abuse 
13 such as opioids, cocaine, amphetamines and cannabinoids 
14 had their roots in traditional medicine, where they had 
15 and still have therapeutic roles, but their use is tightly 
16 regulated. Designer drugs are essentially  chemical ana- 
17 logues of some of these controlled substances, ‘designed’ 
18 as it were, to provide a similar experience to the parent 
19 compound. Initially fuelled by the demand to replicate 
20 the  highs produced  by opioids, this trend  fell out  of 
21 favour following the discovery of the now well-known 
22 neurotoxin  MPTP  (1-methyl-4-phenyl-1,2,3,6-tetrahy- 
23 dropyridine)   produced   in   the   synthesis   of   MPPP 
24 (1-methyl-4-phenyl-4-propionoxypiperidine), a reverse es- 
25 ter of pethidine. This contaminant destroys dopaminergic 
26 neurons, thus chemically inducing Parkinson’s disease. 
27 The next era of designer drugs involved the manipu- 
28 lation of amphetamine, producing an array of 
substances 
29 that energise the consumer and elicit feelings of euphoria 
30 and empathy. The terms ‘empathogens’ or ‘entactogens’ 
31 were used to describe these phenethylamine compounds 
32 to which ecstasy belongs. Although not a designer drug as 
33 such, gamma-hyroxybutyrate  was also popular in the club 
34 scene but  once its status changed to  being a schedule 
35 drug, it too underwent modification and gamma butyro- 
36 lactone became prevalent. Tryptamine derivatives were 
37 also available in the 1990s alongside the phenethylamines. 
38 In the early 2000s, piperazine compounds arrived after 
39 being  considered  unsuitable  for  therapeutic  use  by 
40 pharmaceutical companies. Further trawling of the lines 
41 of  failed  pharmaceutical products  for  potential  ‘legal 
42 highs’  yielded   the   cathinone   derivatives  including 
43 mephedrone.  As   these  products  were  derived  from 
44 chemicals obtainable from legal sources, their promulga- 
45 tion and distribution became more extensive. 
46 
47 Toxidrome 48 
49 Most of the newer substances of abuse have actions at 
 
50 multiple receptor types but may differ in their patterns of 
51 effects  [6].  Drugs  that  produce  a  sympathomimetic 
52 syndrome do so by inhibiting reuptake of catecholamines, 
53 eliciting  mainly  stimulatory  effects  in  the  user  and 
examples of such agents include benzylpiperazine, 
mephedrone and diphenylprolinol. Other drugs act 
predominately on the serotonergic system and thus 
manifest signs of serotonin syndrome in toxicity. Those 
agents that tend to  produce entactogenic feelings (e.g. 
phenylpiperazines, methylone) do so by causing serotonin 
release in the CNS  whereas those with hallucinogenic 
properties (e.g.  5-methoxy-N,N-diisopropyltryptamine, 
2,5-dimethoxy-4-bromoamfetamine) are serotonin 
receptor agonists [6]. 
 
 
Cannabinoids 
 
Cannabis is probably one  of the  most frequently used 
recreational drugs and is consumed as a mixture of dried 
shredded flowers and leaves of the hemp plant Cannabis 
sativa (marijuana), as  resinous secretions  of the cannabis 
plant (hashish) or synthetically as  a yellow resinous  oil 
(dronabinol). Delta-9-tetrahydrocannabinol (THC) is 
believed  to  be  the  most  psychoactive component  of 
cannabinoids contained in cannabis. Although its toxico- 
logical effects may be familiar to some, it is worth bearing 
in  mind  that  advances in  cultivation  methods  have 
enabled higher THC  yield from plants and that hashish 
oil or resin can contain a very high quantity of THC. This 
potentially would increase the likelihood of more signif- 
icant  levels in  the  blood  and  enhanced  intoxication. 
Although risk perception following cannabis use is less 
impaired than with alcohol, it is one of the most common 
drugs detected in drivers involved in motor vehicle 
accidents [7]. 
Given the prevalence of its use, it has been suggested 
that a history of illicit drug and especially cannabis use 
should be obtained routinely in the pre-anaesthetic 
assessment, although patients may be reticent to disclose 
it [8]. It is also difficult to predict the degree of 
intoxication as this is not linearly related to plasma levels 
[9]. The nature of the interaction between the sedative 
effects of cannabis  and general anaesthesia may not  be 
easily predictable. There is a lack of data in humans but 
animal  studies indicate  that  THC   may  prolong  the 
sedative effect of  general anaesthesia [10,  11].  Acute 
intoxication  with  agitation can  be  treated  with  ben- 
zodiazepines or,  probably  more  safely, with  alpha-2 
agonists [12].  Smoking  marijuana  leads to  a  greater 
respiratory burden  of  carbon  monoxide  and  tar  than 
smoking a similar quantity of tobacco [13]; it  is also 
claimed that it causes more airway irritation due to the 
higher temperature at which marijuana leaves burn [14]. 
Therefore,  one  should  be  prepared  for  dealing with 
airway  complications such  as   bronchospasm. Recent 
inhalation  of  marijuana smoke  before  anaesthesia has 
been associated with uvular oedema [15]. Tachycardia is 
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1 probably the most common cardiovascular problem but 
2 postural hypotension may occur at higher doses. Seizures 
3 can also occur. 
4 
5 
6 Cocaine 
7 
8 Cocaine is available  as the hydrochloride salt that can be 
9 injected or snorted or as free base (‘crack’) which can be 
10 smoked. This drug inhibits reuptake of noradrenaline and 
11 dopamine in sympathetic nerve endings and in the brain to 
12 produce  a  feeling  of  excitement  and  pleasure.  This 
13 accumulation of catecholamines  at the nerve endings is 
14 also responsible for an array of cardiovascular side effects, 
15 including  tachycardia,  hypertension,  arrhythmias  and 
16 myocardial ischaemia. It may even precipitate myocardial 
17 infarction in up to 6% of patients presenting with chest 
18 pain [16]. At higher doses, it may cause depression of 
19 myocardial  contractility.  Fever  may  also  be  present, 
20 generated from  a  combination  of  altered temperature 
21 regulation, vasoconstriction and motor agitation. There is 
22 also a reduction in seizure threshold. The  human liver 
23 combines  cocaine  and  alcohol  to   produce   a  third 
24 substance, cocaethylene, which intensifies cocaine’s eu- 
25 phoric effects and has a significantly  longer duration of 
26 action compared with the parent compound [9]. Unfor- 
27 tunately, the prevalence of cocaine abuse in the young is 
28 astoundingly high,  with  90% of female abusers falling 
29 within child bearing age [17]; thus, providing anaesthesia 
30 for the cocaine affected patient may not be a rare event. 
31 It is advisable to control the patient’s blood pressure 
32 before   anaesthesia  induction   to   avoid   hypertensive 
33 responses to intense stimulation such as intubation. Pre- 
34 operative control  of anxiety by using benzodiazepines 
35 may  help  alleviate  emotional  stress. The   choice  of 
36 vasoactive agents is challenging. Beta-adrenoceptor antag- 
37 onist use alone may not be effective as it may still leave 
38 unopposed   alpha-adrenoceptor  stimulation.  Labetalol 
39 appears therefore to be a more logical choice but its use 
40 is also controversial as  it  is a  relatively weak  alpha- 
41 adrenoceptor antagonist. Vasodilators such as hydralazine 
42 result in reflex tachycardia, undesirable in the context of 
43 cocaine-induced tachycardia. The  central sympatholytic 
44 and sedative properties of dexmedetomidine may make 
45 this drug a reasonable choice in this context. There have 
46 been a number of case reports where dexmedetomidine 
47 has been successfully used to manage hypertension and 
48 central nervous system (CNS)  excitability from  with- 
49 drawal  of  cocaine  and  opioids  where   other   more 
50 traditional  agents  have  failed  [18].  Being  a  potent 
 51 
sympathomimetic, ketamine can potentiate the  cardio- 
52 vascular toxicity  of  cocaine.  Temperature  should  be 
53 carefully monitored. Animal studies indicate that cocaine 
can increase the minimal alveolar concentration (MAC) 
requirement  using halothane  in  rats and  isoflurane in 
sheep [19, 20]. Anaesthesia for non-intoxicated patients 
with urine positive for cocaine metabolites appears to be 
safe if the QTc interval is less than 500 ms [21]. 
Regional anaesthesia may be difficult to perform in the 
cocaine abusing patient. Combative behaviour and altered 
sensorium may preclude one  from obtaining informed 
consent or getting cooperation to perform certain blocks 
or procedures. Cocaine use can induce thrombocytopae- 
nia [22] but a formal platelet count is probably unnec- 
essary for an otherwise healthy cocaine user. 
Hypertension or hypotension may occur with the latter 
requiring direct vasopressors  such as  phenylephrine for 
control.  There  may  be  altered pain  perception  from 
changes in opioid receptor density [23]. 
 
 
 
Amphetamines 
 
The  term amphetamine is short for alpha-methylphen- 
ethylamine and these are essentially a group of indirectly 
acting sympathomimetic compounds with powerful CNS 
stimulating effects. Various compounds of  abuse have 
been synthesised from this molecule with various substi- 
tutions. One  of the better known  drugs in this class  is 
‘Ecstasy’, the name of which can be a rather undifferen- 
tiated term used to describe several compounds related to 
MDMA (3,4 –methylenedioxymethamphetamine). 
Chemically they resemble adrenaline and dopamine 
which is reflected in their biological effects. Furthermore, 
the methylenedioxy (-O-CH2-O-)  substitution on  the 
aromatic ring confers properties akin to the hallucinogen 
mescaline [24]. Thus, the popularity of Ecstasy is its ability 
to elevate the user’s energy levels in addition to enhancing 
mood with feelings of euphoria and empathy. 
Methylenedioxymethamphetamine  causes  an   acute 
increase in  serotonin,  noradrenaline and  dopamine  in 
synaptic junctions  from  both  increased secretion  and 
reduced reuptake. This leads to a depletion of stores that 
accompany the withdrawal of the drug. As these neuro- 
transmitters are involved with the control of mood, 
thermoregulation,  sleep and  appetite,  it  explains  the 
pleasurable and undesirable effects of Ecstasy. Typically it 
has an onset of an hour after oral ingestion with effects 
lasting 4–6 h, and a plasma half-life of around 7 h. Blood 
levels often do not  correlate well with the severity of 
systemic effects. After withdrawal from Ecstasy, users may 
feel very tired and low and need a long period of sleep to 
recover. Major side effects include hyperpyrexia from 
over exertion or from central activation of heat gener- 
ation and conservation mechanisms with consequent 
rhadomyolysis. There is some anecdotal evidence for the 
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1 use  of  Dantrolene  to  assist cooling  [25].  Serotonin 
2 syndrome, hyponatraemia, isolated liver failure, cerebro- 
3 vascular  accident or  sudden death  may  also be  seen. 
4 Hyponatraemia results from excessive drinking of hypo- 
5 tonic fluids by users to prevent hyperthermia as well as 
6 increased  antidiuretic  hormone   secretion  [26].  Liver 
7 failure  can  occur  as   part  of  the  multi-organ  failure 
8 accompanying rhabdomyolysis or may be the result of an 
9 idiosyncratic immune-mediated reaction [27]. Serotonin 
10 syndrome may even cause hyperthermia in those who are 
11 not engaged in vigorous activity. 
12 Toxic  reactions  should  be  managed  with  general 
13 supportive measures and careful monitoring of vital signs 
14 depending on stage of presentation. Life threatening and 
15 major cardiovascular metabolic disturbances  should be 
16 attended  to  first, where  possible, before administering 
17 general anaesthesia. The use of labetalol may be preferable 
18 over beta-adrenoceptor antagonists alone as the use of the 
19 latter results in unopposed alpha-1 adrenoceptor agonism. 
20 Judicious use of  intravenous fluids is required  as  the 
21 hydration status of the patient may undergo rapid flux 
22 dependent  upon  pre-admission water  consumption  or 
23 activity and on-going body temperature elevation. Along 
24 the same lines, serum sodium should be closely moni- 
25 tored.   A  hyperadrenergic  state  accompanying  acute 
26 amphetamine   intoxication   may   increase  MAC   but 
27 chronic use may decrease it [28]. The patient’s temper- 
28 ature  must  be  carefully monitored.  Hypotension  may 
29 require direct acting catecholamines, like phenylephrine, 
30 but response may be unpredictable. 
31 A diagnostic challenge occurs when  hyperadrenegic 
32 states induced by acute amphetamine or cocaine intox- 
33 ication presents in the late term parturient, the symptoms 
34 of which are difficult to distinguish from pre-eclampsia or 
35 eclampsia [29]. Liver and renal function tests and, where 
36 available, rapid urine screen for cocaine metabolites may 
37 aid in the differential diagnosis. 
38 
39 
40 New psychoactive substances 
41 
42 Legal highs refer to substances with psychoactive prop- 
43 erties which are not yet scheduled  as controlled substances 
44 and therefore can be sold freely, either on the internet or 
45 by ‘head shops’. They are new only in the sense that their 
46 potential abuse is newly discovered as some compounds 
47 have been  in  existence for many years. They  can be 
48 marketed  as  bath  salts or  plant  food  and  are  usually 
49 marked ‘not for human consumption’ to avoid regulatory 
50 countermeasures. Although  originating  from  a  rather 
 51 
diverse background, as a group the members bear some 
52 chemical  similarities to  endogenous   neurotransmitters 
53 such as  dopamine or serotonin, or to existing drugs of 
abuse such as amphetamines  [30]. They can be synthesised 
with relative ease from compounds, the majority of which 
can  be  obtained  legally in  reasonable quantities from 
commercial suppliers.  As quality control is not a priority 
of  recreational drug  laboratories, toxic  levels of  these 
substances may be reached accidentally in consumers. 
 
 
Cathinone compounds 
 
One class of compounds to emerge among the designer 
drug scene early this millennium is the cathinone 
derivatives. Cathinone is a psychostimulant derived from 
fresh leaves of the khat shrub, a plant that is naturally 
found in Africa and the Arabian peninsula, where the 
practice of chewing these leaves to obtain a high has been 
around for many centuries. Just before the isolation of the 
active ingredient from the  plant in  1930, two  related 
synthetic compounds,  ephedrone  (methcathinone)  and 
mephedrone  (4 methylmethcathinone) were produced, 
the former being marketed as  an antidepressant in the 
USSR [31]. Cathinone was only later isolated from khat 
in 1975, and the  abuse potential of cathinone-derived 
products was soon recognised, leading to a number (but 
not all of) its related compounds being restricted. 
Mephedrone had been popular among abusers and it is 
snorted or, more commonly, swallowed either neat or 
dissolved in a beverage to avoid nose burns. The duration 
of  effect is 2–4 h  after oral  ingestion.  From  in  vitro 
synaptosomal studies, cathinone-related compounds ap- 
pear to augment the release of dopamine and noradren- 
aline [32]. They appear to have a more potent inhibitory 
effect on monoamine oxidase when compared with 
amphetamines but a less pronounced effect on serotonin 
release and reuptake. 
Upon consumption, they produce psychostimulatory  as 
well  as  hallucinogenic effects, with  an  accompanying 
peripheral cardiovascular effect attributable to sympathetic 
activation. In this way, their effects are somewhat similar 
to those seen with amphetamine use. The toxic conse- 
quences are therefore extensions of these pharmacody- 
namic properties and deaths have been  attributable to 
their use. 
 
 
Piperazine compounds 
 
Similar to other ‘designer’ drugs, piperazine compounds 
began life as failed therapeutics. Originally developed as 
an antihelminth, it was later investigated as  an antide- 
pressant when its potential abuse was recognised because 
it has similar effects to amphetamines. Benzylpiperazine 
has  a  predominately  dopaminergic  effect  causing the 
release of this neurotransmitter as well as serotonin from 
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1 neurons [33]. In vitro  studies also suggest that it causes 
2 noradrenaline release from peripheral sympathetic nerve 
3 fibres. The other popular piperazine compound trifluo- 
4 romethylphenylpiperazine acts more on the serotoniner- 
5 gic system by  binding its receptors  and  inhibiting its 
6 reuptake. When taken together, it emulates the effect of 
7 Ecstasy. Like  other   designer  drugs,  the  relationship 
8 between toxicity and dose is not always predictable [33]. 
9 
10 
Tryptamines 11 
12 Understandably there are many gaps in the pharmaco- 
13 logical and toxicological profiles of these compounds in 
14 humans,  as   the  identity,  purity,  doses  and  time  of 
15 ingestion by affected patients are not known. Therefore, 
16 the interaction these may have with anaesthesia is even 
17 more of an unknown  quantity. However, a number of 
18 these agents mimic the  actions  of endogenous neuro- 
19 transmitters as well as inhibiting their reuptake. It stands 
20 to reason that precautions similar to those exercised for 
21 patients  on   monoamine  oxidase  inhibitors,  selective 
22 serotonin reuptake inhibitors or selective noradrenaline 
23 reuptake inhibitors, should be taken for patients suspected 
24 to have consumed these drugs. Their sympathomimetic 
25 effects render  gauging depth  of  anaesthesia by  purely 
 
26 3 haemodynamic means a difficult undertaking. Although 
27 depth of anaesthesia monitoring may theoretically miti- 
28 gate some of this difficulty, the intrinsic effect of these 
29 stimulants on the processed EEG is not known. Having 
30 reuptake inhibitor ability, it is not known whether these 
31 agents accentuate endogenous catecholamine responses. 
32 
33 
34 Recent developments in the general 
35 management of poisoning 
36 Much of the acute management of poisoning occurs in 
37 the emergency department or intensive care unit and has 
38 been extensively covered in toxicology texts. In general, a 
elimination. Substances amenable to removal by dialysis 
are generally those which are water soluble and small. 
However, most psychoactive substances are, by nature, 
lipid soluble to facilitate passage  across the blood brain 
barrier. Since the introduction of intravenous lipid 
emulsion (ILE) as  a rescue therapy for local anaesthetic 
overdose, there have been a number of reports of ILE 
improving  level  of  consciousness after  overdoses  of 
psychotropic drugs thus averting the need for intubation 
and ventilation [34–36]. Of particular interest is a report 
of improvement in cardiovascular stability following ILE 
administration in a patient with cocaine overdose [37]. 
One of the proposed mechanisms of efficacy involves an 
expanded plasma lipid phase in reducing free drug levels. 
In  vitro  modelling studies predict  that  the  more  lipid 
soluble and the larger a drugs volume of distribution, the 
greater will be the decrease in serum concentration after 
lipid administration [38]. However, under certain animal 
experimental conditions, ILE can  actually deepen  the 
depth of thiopental-induced anaesthesia, thus challenging 
this simplistic view of ILE acting merely as a lipid sink 
[39]. A systematic review of the literature up to June 2009 
drew similar conclusions of possibly some benefits of ILE 
in lipophilic drug overdoses based on mainly case reports 
and animal studies [40, 41]. There have not been reports 
of major adverse reactions among those studies reviewed. 
However,  many undesirable effects of ILE are known 
when it is used as part of total parental nutrition but it is 
not likely that hypersensitivity would present following 
acute administration of ILE [42]. 
Another important aspect of managing psychostimulant 
toxicity is the symptomatic control of cardiovascular and 
CNS overstimulation. The use of the alpha 2 adrenoceptor 
agonist dexmedetomidine for alleviating withdrawal 
symptoms from sedative use has been widely reported. Its 
inhibitory effects on  central sympathetic outflow have 
recently been exploited as a means of attenuating the acute 
sympathomimetic effects of cocaine use. Dexmedetomi- 
)dine at 0.1 and 0.3 lg.kg 1 39 high index of suspicion should be exercised, as  history was able to  attenuate the 
40 from  the  affected individual  is  not  always available. 
41 Poisoning  should  be  considered  in  any  patient  with 
42 inexplicable cardiac, respiratory or metabolic disturbance, 
43 especially when  accompanied by unusual behaviour or 
44 altered sensorium. Irrespective of the substances ingested, 
45 the general steps of resuscitation, substance identification, 
46 reducing   absorption,  increasing  elimination,   specific 
47 treatment including antidote administration and support- 
48 ive measures with a plan for on-going monitoring should 
49 be instituted. 
50 Despite the best of general supportive measures, toxic 
51 levels f  substances may  be  reached  in  some  cases, o
52 potentially necessitating more  invasive techniques  for 
53 
increase in sympathetic nerve activation and skin vascular 
resistance in human volunteers receiving 2 mg.kg)1   of 
intranasal cocaine [43]. Clinically, it has been reported to 
be used successfully in alleviating cocaine-induced hyper- 
tensive crisis in a patient with aortic dissection [44]. From 
the CNS point of view, dexmedetomidine has been shown 
experimentally to counter the decrease in seizure threshold 
from cocaine toxicity [45]. There  is another report of 
dexmedetomidine use in the treatment of agitation 
accompanying overdoses of dextromethorphan and 
MDMA [46]. Thus, this drug has important advantages 
in the management of several aspects of stimulant overdose 
and acute withdrawal syndromes. 
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Conclusions 
 
The  true  extent  of  poisoning with  psychoactive sub- 
stances remains undefined but is likely to be underesti- 
mated. A lack of quality control and changes in 
production techniques can yield illicit drugs with a high 
concentration of the active substance that, in turn, 
increases the potential for eliciting a greater severity of 
toxicity.  This  problem  is  widespread in  society  and 
indications are that  new  designer drugs are becoming 
increasingly available [6]. It is almost inevitable that many 
anaesthetists will be engaged in the care of those poisoned 
by  these  substances. The  acute  cardiac and  cerebral 
toxicity  associated with   cocaine,  amphetamines  and 
cathinone derivatives are mainly attributable to elevated 
concentrations of catecholamines in nerve endings 
subsequent to enhanced release and reduced reuptake to 
various degrees. Haemodynamic instability and changes in 
anaesthetic and analgesia requirements are probably in 
those requiring surgery. While the toxicological profile of 
individual classes of poisons may appear discrete, it is also 
very important to be cognizant of the likelihood of co- 
ingestion of different substances, with the clinical picture 
being  overwhelmed  with  one  major  substance, quite 
often alcohol. The use of intravenous lipid emulsion is 
showing promise in  the  treatment  of drug  overdoses. 
Dexmedetomidine has a promising role as  it dampens 
sympathetic hyperactivity, is analgesic, produces sedation 
and  relieves agitation  without  respiratory depression. 
However, further clinical experience with these agents is 
required to more clearly delineate indications for their 
use. 
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